Longboard Pharmaceuticals Inc (LBPH) Stock Price, Forecast & Analysis
USA - NASDAQ:LBPH - US54300N1037 - Common Stock
LBPH Key Statistics, Chart & Performance
The current stock price of LBPH is 59.98 USD. In the past month the price increased by 0.44%. In the past year, price increased by 1399.5%.
LBPH Latest News, Press Relases and Analysis
LBPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 43.96 | 914.89B | ||
| JNJ | JOHNSON & JOHNSON | 18.15 | 453.76B | ||
| MRK | MERCK & CO. INC. | 9.85 | 216.68B | ||
| PFE | PFIZER INC | 7.62 | 138.67B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.2 | 96.19B | ||
| ZTS | ZOETIS INC | 18.89 | 53.09B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.48B | ||
| VTRS | VIATRIS INC | 4.36 | 11.86B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.2 | 11.06B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.78 | 7.95B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.88B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.71 | 4.10B |
Related stock screener links
About LBPH
Company Profile
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company is headquartered in La Jolla, California and currently employs 50 full-time employees. The company went IPO on 2021-03-12. The firm is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). The company is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The firm plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The company is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The firm is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
Company Info
Longboard Pharmaceuticals Inc
4275 Executive Square, Suite 950
La Jolla CALIFORNIA 92121 US
CEO: Kevin R. Lind
Employees: 50
Phone: 16195929775
Longboard Pharmaceuticals Inc / LBPH FAQ
What does LBPH do?
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company is headquartered in La Jolla, California and currently employs 50 full-time employees. The company went IPO on 2021-03-12. The firm is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). The company is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The firm plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The company is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The firm is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
What is the stock price of Longboard Pharmaceuticals Inc today?
The current stock price of LBPH is 59.98 USD. The price increased by 0.03% in the last trading session.
Does Longboard Pharmaceuticals Inc pay dividends?
LBPH does not pay a dividend.
What is the ChartMill rating of Longboard Pharmaceuticals Inc stock?
LBPH has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is Longboard Pharmaceuticals Inc (LBPH) stock traded?
LBPH stock is listed on the Nasdaq exchange.
How many employees does Longboard Pharmaceuticals Inc have?
Longboard Pharmaceuticals Inc (LBPH) currently has 50 employees.
LBPH Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to LBPH. When comparing the yearly performance of all stocks, LBPH is one of the better performing stocks in the market, outperforming 99.74% of all stocks.
LBPH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LBPH. No worries on liquidiy or solvency for LBPH as it has an excellent financial health rating, but there are worries on the profitability.
LBPH Financial Highlights
Over the last trailing twelve months LBPH reported a non-GAAP Earnings per Share(EPS) of -2.23. The EPS increased by 7.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.7% | ||
| ROE | -27.74% | ||
| Debt/Equity | 0 |
LBPH Forecast & Estimates
13 analysts have analysed LBPH and the average price target is 65.96 USD. This implies a price increase of 9.97% is expected in the next year compared to the current price of 59.98.